Optalysys raises $4 million for genomic research
Optalysys, a start-up pioneering the development of light-speed optical coprocessors, has raised $3.95 million (£3.05m) from undisclosed angel investors.
The company will use the funds to manufacture the first commercially available high-performance computing (HPC) processor based on its patented optical processing technology.
"In many industries today, the demand for faster processing far exceeds the capabilities of conventional computing technology," said Dr. Nick New, CEO of Optalysys.
"Until now, only large universities and organizations have had the means to use this kind of computing muscle.
“Our aim is to make supercomputing levels of processing power accessible to a much wider audience of scientists and researchers - which will promote more rapid advancement in such fields as precision health and machine learning, whilst addressing some of the fundamental limitations of conventional computing."
Because its coprocessor excels at rapid and accurate pattern recognition (required for Big Data processing) and mathematical model generation applications, genomic sequence alignment is the first of many application areas targeted by Optalysys.
On August 31st Optalysys demonstrated the latest prototype for genomic searching at the Genome 10k/Genome Science conference held in Norwich, U.K.
Optalysys partner, The Earlham Institute (EI), presented sequence alignment results that were produced using the Optalysys prototype.
"Our prototype is on track to achieve game-changing improvements to process times over current methods whilst providing high levels of accuracy that are associated with the best software processes," said Emma Blaylock, director, chief commercial officer at Optalysys.